Literature DB >> 25183290

Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.

Keng Lim Ng1, Chong Beng Chua2.   

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) has been a proven and effective immunotherapy treatment for superficial transitional cell carcinoma (TCC) of the bladder, especially for high-grade tumors and carcinoma in situ. Nevertheless, significant side effects are associated with BCG instillations, including fever, myalgia, malaise, dysuria, hematuria, and irritable lower urinary tract symptoms. We herein report the case of a patient who developed Reiter's syndrome following intravesical BCG instillations. A 39-year-old Chinese man presented with a 3-week history of dysuria, suprapubic pain, and pain at the tip of the penis postmicturition. Initial investigations revealed that he had microhematuria, and an ultrasound with computed tomography scan of the abdomen showed a bladder mass. Transurethral resection of the bladder tumor was performed and the patient received a single dose of intravesical mitomycin postoperatively. Results of histopathological examination revealed high-grade bladder TCC (G3pT1), and the patient was managed with intravesical BCG for 2 weeks following the surgery. Four weekly cycles of BCG were administered uneventfully; however, before the fifth instillation, the patient complained of urethral discharge, bilateral conjunctivitis, and low back pain. Reiter's syndrome was diagnosed as a rare but known complication of BCG instillation and the BCG immunotherapy was withheld. The patient was treated with nonsteroidal antiinflammatory drugs (for back pain) and eye ointment (for conjunctivitis) and his condition improved. This case report of Reiter's syndrome should be highlighted as a rare but significant complication of BCG immunotherapy and urologists should have a high index of suspicion to diagnose this rare complication.
Copyright © 2017. Published by Elsevier Taiwan.

Entities:  

Keywords:  Bacillus Calmette–Guérin; Reiter's syndrome; intravesical

Mesh:

Substances:

Year:  2014        PMID: 25183290     DOI: 10.1016/j.asjsur.2014.01.016

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  6 in total

Review 1.  Reactive Arthritis following Bacillus Calmette-Guerin Therapy for Bladder Cancer: a Systematic Literature Review.

Authors:  Kawther Ben Abdelghani; Lilia Nacef; Saoussen Miladi; Meriem Sellami; Kmar Ouenniche; Leila Souabni; Selma Kassab; Selma Chekili; Alia Fazaa; Ahmed Laatar
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 2.  Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

Authors:  Neelam Mukherjee; Esther Julián; Jordi B Torrelles; Robert S Svatek
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 4.169

Review 3.  BCG: a vaccine with multiple faces.

Authors:  Marco Antonio Yamazaki-Nakashimada; Alberto Unzueta; Luisa Berenise Gámez-González; Napoleón González-Saldaña; Ricardo U Sorensen
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

4.  Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications.

Authors:  Neelam Mukherjee; Karen M Wheeler; Robert S Svatek
Journal:  Curr Opin Urol       Date:  2019-05       Impact factor: 2.808

5.  Approaching Reactive Arthritis Associated With Poor Prognostic Factors: A Case Report and Literature Review.

Authors:  Swetha Ann Alexander; Eunjung Kim; Ranadeep Mandhadi
Journal:  Cureus       Date:  2021-02-25

6.  [History of reactive arthritis. Historical milestones and future].

Authors:  H Zeidler
Journal:  Z Rheumatol       Date:  2022-08-25       Impact factor: 1.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.